3D model (JSmol)
|Molar mass||373.23 g·mol−1|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Ridazolol is a pharmaceutical drug acting as a beta adrenergic receptor antagonist. It was investigated in the 1980 and 90s for its effects on coronary heart disease and essential hypertension (high blood pressure).
It is not known to be marketed anywhere in the world.
- Fach, WA; Starke, E; Becker, HJ (1992). "Duration of the effect and dose-response relationship of ridazolol in patients with coronary heart disease". Zeitschrift für Kardiologie. 81 (6): 320–5. PMID 1353933.
- Rommel, Th.; Demisch, L. (1994). "Influence of chronic ?-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension". Journal of Neural Transmission. 95 (1): 39–48. doi:10.1007/BF01283029. PMID 7857585. S2CID 31936176.
- "Ridazolol search results". Drugs.com. Retrieved 2021-03-31.